Sort:
Open Access Research Article Issue
Peroxisome proliferator-activated receptors-mediated diabetic wound healing regulates endothelial cells’ mitochondrial function via sonic hedgehog signaling
Burns & Trauma 2025, 13(11): tkaf063
Published: 10 September 2026
Abstract PDF (3.4 MB) Collect
Downloads:0
Background

Diabetic foot ulcer (DFU) is a common and debilitating complication of diabetes, often leading to delayed wound healing. The peroxisome proliferator-activated receptors (PPARs) play a crucial role in regulating cellular metabolism and promoting angiogenesis. This study aims to elucidate the mechanisms through which the activation of PPARs enhances wound healing, particularly under diabetic conditions, as these mechanisms remain inadequately understood.

Methods

Differentially expressed genes in DFU wounds and normal skin tissues were identified using the GEO database. PPAR expression in DFU neovascularization was validated by quantitative reverse transcription polymerase chain reaction, immunofluorescence, and western blotting. In vivo, diabetic mice treated with PPAR agonists (chiglitazar) underwent wound healing assessment, including collagen deposition and angiogenesis. In vitro, advanced glycation end-products (AGEs)—induced endothelial cell models were used to evaluate PPAR activation effects on cell migration, tube formation, and mitochondrial function. Whole transcriptome sequencing and mitochondrial analysis were performed to explore the underlying mechanisms, particularly the sonic hedgehog (SHH)–mitochondrial axis.

Results

PPAR expression was significantly downregulated in DFU tissues (p < 0.05), and PPAR activation in diabetic mice enhanced wound healing, collagen deposition, granulation tissue proliferation, and angiogenesis (p < 0.05). In vitro, PPAR activation protected endothelial cells, promoting vascular endothelial growth factor-A (VEGF-A) and CD31 expression, reducing apoptosis, and enhancing cell migration and tube formation (p < 0.05). Mechanistically, PPARs activated mitochondrial oxidative phosphorylation and membrane function through the SHH signaling pathway. SHH gene silencing reversed the effects of PPAR activation on mitochondrial function and angiogenesis.

Conclusions

PPAR signaling plays a critical role in DFU healing, with its inhibition linked to vascular dysfunction. Activation of the PPARs/SHH–mitochondrial axis significantly enhances endothelial cell metabolism and angiogenesis. This study provides insights into the molecular mechanisms of diabetic wound healing and supports the clinical potential of PPAR agonists for DFU treatment.

Open Access Research Article Issue
Hemoglobin integrated red blood cell membrane-coated metal-organic framework nano-platform for improving the self-adaptive blood glucose management
Nano Research 2025, 18(1): 94907078
Published: 25 December 2024
Abstract PDF (14.3 MB) Collect
Downloads:340

Diabetes, a prevalent chronic metabolic disorder, often leads to severe complications. Currently, existing treatment methods may pose life-threatening risks due to poor patient compliance and inaccurate dosing of subcutaneous insulin injections. Hence, a biomimetic red blood cell (RBC) membrane-coated glucose-responsive nanoplatform is developed for controlling insulin release. Functionalizing nanoplatforms with RBC membrane can prolong the half-life of nano-formulation in vivo mediated by the biomimetic immune escape. Simultaneously, the cascade catalytic effect of glucose oxidase (GOx) encapsulated in metal-organic frameworks (MOFs) and hemoglobin (Hb) in the RBC membrane are able to not only facilitate glucose-responsive insulin release, but also eliminate the detrimental by-product hydrogen peroxide (H2O2) resulting from the Hb mediated H2O2 scavenging. Both in vitro and in vivo studies have demonstrated the favorable glucose-responsive performances of this advanced nano-platform with a single intravenous injection maintaining blood glucose balance in Type 1 Diabetes (T1D) mice for an extended duration without the hypoglycemia risk. Therefore, this biomimetic insulin delivery system is poised to function as a strategy for the intravenous insulin administration, offering a promising drug candidate for the self-adaptive long-term T1D treatment.

Total 2